{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:56:10Z","timestamp":1790686570169,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004897","name":"EORTC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004897","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Pfizer Inc"},{"DOI":"10.13039\/501100005026","name":"Stichting tegen Kanker","doi-asserted-by":"publisher","award":["P2012-209"],"award-info":[{"award-number":["P2012-209"]}],"id":[{"id":"10.13039\/501100005026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004897","name":"EORTC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Bingham Mayne and Smith Ltd"},{"name":"EORTC Cancer Research Fund"},{"DOI":"10.13039\/501100005026","name":"Stichting tegen Kanker","doi-asserted-by":"publisher","award":["P2012-209"],"award-info":[{"award-number":["P2012-209"]}],"id":[{"id":"10.13039\/501100005026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.ejca.2017.10.014","type":"journal-article","created":{"date-parts":[[2017,11,14]],"date-time":"2017-11-14T23:45:34Z","timestamp":1510703134000},"page":"147-163","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":106,"special_numbering":"C","title":["Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial"],"prefix":"10.1016","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5980-030X","authenticated-orcid":false,"given":"Patrick","family":"Sch\u00f6ffski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Wozniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Escudier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Rutkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Anthoney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jozef","family":"Sufliarsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"van Herpen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars H.","family":"Lindner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktor","family":"Gr\u00fcnwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Branko","family":"Zakotnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyne","family":"Lerut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Debiec-Rychter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Marr\u00e9aud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3001-0157","authenticated-orcid":false,"given":"Michela","family":"Lia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiana","family":"Raveloarivahy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Collette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Albiges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2017.10.014_bib1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1476-4598-13-39","article-title":"Molecular subtyping of metastatic renal cell carcinoma: implications for targeted therapy","volume":"13","author":"Wang","year":"2014","journal-title":"Mol Cancer"},{"key":"10.1016\/j.ejca.2017.10.014_bib2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.eururo.2014.04.029","article-title":"Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity","volume":"67","author":"Shuch","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejca.2017.10.014_bib3","doi-asserted-by":"crossref","first-page":"5628","DOI":"10.1158\/0008-5472.CAN-05-0533","article-title":"A molecular classification of papillary renal cell carcinoma","volume":"65","author":"Yang","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2017.10.014_bib4","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0002-9440(10)64260-5","article-title":"Unique patterns of allelic imbalance distinguish type 1 from type 2 sporadic papillary renal cell carcinoma","volume":"161","author":"Sanders","year":"2002","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ejca.2017.10.014_bib5","first-page":"537","article-title":"Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors","volume":"10","author":"Delahunt","year":"1997","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ejca.2017.10.014_bib6","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1056\/NEJMoa1505917","article-title":"Comprehensive molecular characterization of papillary renal-cell carcinoma","volume":"374","author":"Cancer Genome Atlas Research Network","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2017.10.014_bib7","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.eururo.2005.11.035","article-title":"2004 WHO classification of the renal tumors of the adults","volume":"49","author":"Lopez-Beltran","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejca.2017.10.014_bib8","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1097\/01.ju.0000081122.57148.ec","article-title":"Prognostic factors for the survival of patients with papillary renal cell carcinoma: meaning of histological typing and multifocality","volume":"170","author":"Mejean","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.ejca.2017.10.014_bib9","article-title":"Guidelines on renal cell carcinoma","author":"Ljungberg","year":"2014","journal-title":"Eur Assoc Urol"},{"key":"10.1016\/j.ejca.2017.10.014_bib10","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1016\/j.ejca.2012.05.002","article-title":"Incidence and long-term prognosis of papillary compared to clear cell renal cell carcinoma-a multicentre study","volume":"48","author":"Steffens","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2017.10.014_bib11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/ng.3146","article-title":"Spectrum of diverse genomic alterations define non\u2013clear cell renal carcinoma subtype","volume":"47","author":"Durinck","year":"2015","journal-title":"Nat Genet"},{"issue":"13","key":"10.1016\/j.ejca.2017.10.014_bib12","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1158\/1078-0432.CCR-13-2173","article-title":"MET is a potential target across all papillary renal cell carcinomas: result from a large molecular study of pRCC with CGH array and matching gene expression array","volume":"20","author":"Albiges","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2017.10.014_bib13","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1200\/JCO.2012.43.3383","article-title":"Phase II and biomarker study of the dual MET\/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma","volume":"31","author":"Choueiri","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.10.014_bib14","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1158\/1078-0432.CCR-08-1306","article-title":"Novel therapeutic inhibitors of the c-Met signaling pathway in cancer","volume":"15","author":"Eder","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2017.10.014_bib15","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/nrclinonc.2012.71","article-title":"MET: a promising anticancer therapeutic target","volume":"9","author":"Peters","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.ejca.2017.10.014_bib16","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1177\/1758834011422556","article-title":"An overview of the c-MET signaling pathway","volume":"3","author":"Organ","year":"2011","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.ejca.2017.10.014_bib17","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/ng0597-68","article-title":"Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas","volume":"16","author":"Schmidt","year":"1997","journal-title":"Nat Genet"},{"key":"10.1016\/j.ejca.2017.10.014_bib18","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1038\/sj.onc.1202547","article-title":"Novel mutations of the MET proto-oncogene in papillary renal carcinomas","volume":"18","author":"Schmidt","year":"1999","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2017.10.014_bib19","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/1097-0142(19950815)76:4<669::AID-CNCR2820760420>3.0.CO;2-U","article-title":"Papillary renal tumors. Morphologic, cytochemical, and genotypic features","volume":"76","author":"Lager","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2017.10.014_bib20","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/658767","article-title":"Familial renal cancer: molecular genetics and surgical management","author":"Barrisford","year":"2011","journal-title":"Int J Surg Oncol"},{"key":"10.1016\/j.ejca.2017.10.014_bib21","doi-asserted-by":"crossref","first-page":"671s","DOI":"10.1158\/1078-0432.CCR-06-1870","article-title":"Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics","volume":"13","author":"Linehan","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2017.10.014_bib22","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.eururo.2012.06.043","article-title":"A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma","volume":"62","author":"Tannir","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejca.2017.10.014_bib23","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1200\/jco.2014.32.4_suppl.410","article-title":"Open-label, phase II RAPTOR study of everolimus (EVE) for papillary mRCC: efficacy in type 1 and type 2 histology","volume":"4","author":"Escudier","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.10.014_bib24","doi-asserted-by":"crossref","first-page":"5788","DOI":"10.1200\/JCO.2008.18.8821","article-title":"Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317","volume":"27","author":"Gordon","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.10.014_bib25","first-page":"1477","article-title":"Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases","volume":"11","author":"Rodig","year":"2010","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.ejca.2017.10.014_bib26","first-page":"107","article-title":"Predicting resistance by selection of signaling pathways","volume":"3","author":"Karachaliou","year":"2014","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.ejca.2017.10.014_bib27","doi-asserted-by":"crossref","DOI":"10.4172\/2157-2518.1000173","article-title":"EGFR and c-Met inhibitors are effective in reducing tumorigenicity in cancer","author":"Stone","year":"2014","journal-title":"J Carcinog Mutagen"},{"issue":"Suppl.","key":"10.1016\/j.ejca.2017.10.014_bib28","first-page":"5s","article-title":"Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC)","volume":"32","author":"Camidge","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.10.014_bib29","unstructured":"Crizotinib summary of product characteristics (SPC). Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002489\/WC500134759.pdf [Accessed 22 April 2016]."},{"key":"10.1016\/j.ejca.2017.10.014_bib30","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1093\/annonc\/mdv149","article-title":"First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)","volume":"26","author":"Ravaud","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2017.10.014_bib31","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.72.2967","article-title":"Biomarker-based phase II trial of savolitinib in patients with advanced papillary renal cell cancer","author":"Choueiri","year":"2017","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917313540?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917313540?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,25]],"date-time":"2018-10-25T18:32:16Z","timestamp":1540492336000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804917313540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":31,"alternative-id":["S0959804917313540"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2017.10.014","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2017.10.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}